^
Association details:
| Biomarker: | EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) + uliledlimab (TJD5) (CD73 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Uliledlimab and toripalimab combination therapy in treatment naive advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker.
Published date:
05/25/2023
Excerpt:
Pts with treatment naïve advanced NSCLC (EGFR/ALK wild type) were enrolled in a dose-expansion cohort and received uliledlimab (20mg/kg or 30mg/kg Q3W) in combination with toripalimab...While ORR and DCR were 31.3% (15/48) and 79.2% (38/48) respectively in all pts, ORR appeared higher in CD73High pts (50%, 9/18) and much lower in CD73Low pts (14.8%, 4/27). Highest ORR was found in a cohort with CD73High and PD-L1 TPS≥1% (57.1%, 8/14)....Uliledlimab and toripalimab combination therapy was well-tolerated in treatment naïve advanced NSCLC pts. Clinical response of the therapy seems to correlate with high tumor CD73 expression, indicating a potential value of CD73 as a predictive biomarker.
DOI:
10.1200/JCO.2023.41.16_suppl.2570
Trial ID:
